Lupus clinical trials at UCSF
7 in progress, 1 open to new patients

  • JBT-101 in Systemic Lupus Erythematosus (SLE)

    open to eligible people ages 18-70

    The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101 (also known as lenabasum) in systemic lupus erythematosus (SLE). - One hundred adults with active joint disease and at least moderate pain will be enrolled in this study to evaluate treatment of their systemic lupus erythematosus (SLE) with JBT-101. JBT-101 is a synthetic endocannabinoid receptor type 2 (CB2) agonist and an activator of the body's normal processes, to resolve innate immune responses without immunosuppression. - Participants will receive 2 doses of JBT-101 by mouth (three groups of varying doses) or, placebo, for 84 days and will continue to be followed for an additional 28 days. Participant visits to assess endpoints occur on Day 1, then every 2 weeks twice, then every 4 weeks three times, for a total of six visits. - The change in maximum daily pain Numerical Rating Scale (NRS) score from Baseline (Visit 1) will be assessed at every visit.

    San Francisco, California and other locations

  • A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE

    Sorry, in progress, not accepting new patients

    To compare the effect of RAYOS® versus immediate-release (IR) prednisone on fatigue as measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).

    San Francisco, California and other locations

  • Autologous Polyclonal Tregs for Lupus

    Sorry, in progress, not accepting new patients

    The primary purpose of this Phase 1 study is to evaluate the safety, tolerability, and effect of 3 different doses of Treg therapy in adults with skin (cutaneous) involvement of their lupus. Targeting cutaneous disease offers the ability to control background therapy, readily detect clinical effects, and perform research analyses not only in blood but also skin. Safety, disease activity, and mechanism of Tregs will be evaluated. The intent is to support dose selection for a future larger efficacy trial in lupus.

    San Francisco, California

  • Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

    Sorry, in progress, not accepting new patients

    This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.

    San Francisco, California and other locations

  • Rituximab and Belimumab for Lupus Nephritis

    Sorry, in progress, not accepting new patients

    In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab is safe and if this drug combination can block the immune system attacks.

    San Francisco, California and other locations

  • Study to Evaluate the Natural History of Osteoporosis in Children and Adolescents With Systemic Lupus Erythematosus

    Sorry, in progress, not accepting new patients

    This is a study to determine if people with Lupus have weak bones. Test which is a better method for detecting bone changes: - Dual energy X-ray absorptiometry (DXA) - Single energy quantitative computed tomography (SEQCT) Evaluate whether weak bones are associated with things like medications or amount of fat and muscle.

    San Francisco, California

  • Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)

    Sorry, not currently recruiting here

    SPOCS is an international, multicenter, prospective observational cohort study with bi-annual study visits over a 3-year follow-up designed to systematically describe the comprehensive SLE patient-journey regarding clinical features, disease progression and treatment patterns, SLE outcomes, health status assessments (PROs), and health care resource utilization (HCRU) in a general population of moderate-to-severe SLE patients.

    San Francisco, California and other locations

Last updated: